Off-target ACE2 ligands: Possible therapeutic option for CoVid-19?
作者信息
Brogi Simone, Calderone Vincenzo
机构信息
Department of Pharmacy, University of Pisa, Pisa, Italy.
出版信息
Br J Clin Pharmacol. 2020 Jun;86(6):1178-1179. doi: 10.1111/bcp.14343. Epub 2020 May 13.
Abstract
摘要
相似文献
1
Off-target ACE2 ligands: Possible therapeutic option for CoVid-19?脱靶ACE2配体：新冠病毒病的潜在治疗选择？
Br J Clin Pharmacol. 2020 Jun;86(6):1178-1179. doi: 10.1111/bcp.14343. Epub 2020 May 13.
2
Recombinant human ACE2: potential therapeutics of SARS-CoV-2 infection and its complication.重组人血管紧张素转换酶2：新型冠状病毒感染及其并发症的潜在治疗方法
Acta Pharmacol Sin. 2020 Sep;41(9):1255-1257. doi: 10.1038/s41401-020-0430-6. Epub 2020 Jun 24.
3
Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2.新型冠状病毒肺炎疫情时期的心血管药理学：聚焦血管紧张素转换酶 2
J Cardiovasc Pharmacol. 2020 Jun;75(6):526-529. doi: 10.1097/FJC.0000000000000840.
4
Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.针对高融合活性新兴冠状病毒 SARS-CoV-2 的有效膜融合抑制剂设计。
J Virol. 2020 Jul 1;94(14). doi: 10.1128/JVI.00635-20.
5
Can beta-adrenergic blockers be used in the treatment of COVID-19?β-肾上腺素能阻滞剂可用于治疗新型冠状病毒肺炎吗？
Med Hypotheses. 2020 Sep;142:109809. doi: 10.1016/j.mehy.2020.109809. Epub 2020 May 5.
6
Could a specific ACE2 activator drug improve the clinical outcome of SARS-CoV-2? A potential pharmacological insight.一种特定的血管紧张素转换酶2（ACE2）激活剂药物能否改善2019冠状病毒病（SARS-CoV-2）的临床结局？一项潜在的药理学见解。
Expert Rev Clin Pharmacol. 2020 Aug;13(8):807-811. doi: 10.1080/17512433.2020.1798760. Epub 2020 Jul 25.
7
Compensation of ACE2 Function for Possible Clinical Management of 2019-nCoV-Induced Acute Lung Injury.通过补偿血管紧张素转换酶2（ACE2）功能实现对2019新型冠状病毒（2019-nCoV）所致急性肺损伤的潜在临床治疗
Virol Sin. 2020 Jun;35(3):256-258. doi: 10.1007/s12250-020-00205-6. Epub 2020 Feb 7.
8
JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.JAK 抑制作为 COVID-19 患者的一种新治疗策略。
Int Arch Allergy Immunol. 2020;181(6):467-475. doi: 10.1159/000508247. Epub 2020 May 11.
9
The therapeutic potential of targeting ACE2 in COVID-19.靶向 COVID-19 中 ACE2 的治疗潜力。
Eur Rev Med Pharmacol Sci. 2020 Sep;24(18):9744-9747. doi: 10.26355/eurrev_202009_23067.
10
SARS-CoV-2 Pathogenesis: Imbalance in the Renin-Angiotensin System Favors Lung Fibrosis.严重急性呼吸综合征冠状病毒2型发病机制：肾素-血管紧张素系统失衡促进肺纤维化。
Front Cell Infect Microbiol. 2020 Jun 12;10:340. doi: 10.3389/fcimb.2020.00340. eCollection 2020.
引用本文的文献
1
Immunogenicity and Safety of Anti-SARS-CoV-2 mRNA Vaccines in a Cohort of Patients with Hereditary Angioedema.抗SARS-CoV-2 mRNA疫苗在一组遗传性血管性水肿患者中的免疫原性和安全性
Vaccines (Basel). 2023 Jan 18;11(2):215. doi: 10.3390/vaccines11020215.
2
Butein as a potential binder of human ACE2 receptor for interfering with SARS-CoV-2 entry: a computer-aided analysis.作为一种潜在的人ACE2受体结合剂以干扰SARS-CoV-2进入的白杨素：一项计算机辅助分析。
J Mol Model. 2022 Aug 24;28(9):270. doi: 10.1007/s00894-022-05270-0.
3
A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor.一种新型治疗性肽可阻断 SARS-CoV-2 刺突蛋白与宿主细胞 ACE2 受体结合。
Drugs R D. 2021 Sep;21(3):273-283. doi: 10.1007/s40268-021-00357-0. Epub 2021 Jul 29.
4
In silico analysis of RNA-dependent RNA polymerase of the SARS-CoV-2 and therapeutic potential of existing antiviral drugs.基于 SARS-CoV-2 的 RNA 依赖性 RNA 聚合酶的计算机分析及现有抗病毒药物的治疗潜力。
Comput Biol Med. 2021 Aug;135:104591. doi: 10.1016/j.compbiomed.2021.104591. Epub 2021 Jun 23.
5
Computational molecular docking and virtual screening revealed promising SARS-CoV-2 drugs.计算分子对接和虚拟筛选揭示了有前景的抗SARS-CoV-2药物。
Precis Clin Med. 2021 Jan 18;4(1):1-16. doi: 10.1093/pcmedi/pbab001. eCollection 2021 Mar.
6
Does hereditary angioedema make COVID-19 worse?遗传性血管性水肿会使新冠病毒疾病病情加重吗？
World Allergy Organ J. 2020 Sep;13(9):100454. doi: 10.1016/j.waojou.2020.100454. Epub 2020 Aug 10.
本文引用的文献
1
The pivotal link between ACE2 deficiency and SARS-CoV-2 infection.ACE2 缺乏与 SARS-CoV-2 感染之间的关键联系。
Eur J Intern Med. 2020 Jun;76:14-20. doi: 10.1016/j.ejim.2020.04.037. Epub 2020 Apr 20.
2
Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases.新型冠状病毒肺炎及相关人类冠状病毒疾病治疗药物和疫苗的研发
ACS Cent Sci. 2020 Mar 25;6(3):315-331. doi: 10.1021/acscentsci.0c00272. Epub 2020 Mar 12.
3
Coronavirus puts drug repurposing on the fast track.冠状病毒使药物重新利用走上快车道。
Nat Biotechnol. 2020 Apr;38(4):379-381. doi: 10.1038/d41587-020-00003-1.
4
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病：考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
5
Can we contain the COVID-19 outbreak with the same measures as for SARS?我们能否用应对 SARS 的相同措施来控制 COVID-19 疫情？
Lancet Infect Dis. 2020 May;20(5):e102-e107. doi: 10.1016/S1473-3099(20)30129-8. Epub 2020 Mar 5.
6
Therapeutic options for the 2019 novel coronavirus (2019-nCoV).2019新型冠状病毒（2019-nCoV）的治疗选择。
Nat Rev Drug Discov. 2020 Mar;19(3):149-150. doi: 10.1038/d41573-020-00016-0.
7
Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target.血管紧张素转换酶2（ACE2）作为严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的受体：分子机制与潜在治疗靶点
Intensive Care Med. 2020 Apr;46(4):586-590. doi: 10.1007/s00134-020-05985-9. Epub 2020 Mar 3.
8
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.2019 年新型冠状病毒刺突蛋白在预融合构象的冷冻电镜结构
Science. 2020 Mar 13;367(6483):1260-1263. doi: 10.1126/science.abb2507. Epub 2020 Feb 19.
9
Prediction of off-target effects on angiotensin-converting enzyme 2.对血管紧张素转换酶2脱靶效应的预测
J Biomol Screen. 2011 Sep;16(8):878-85. doi: 10.1177/1087057111413919. Epub 2011 Aug 22.
10
ACE2: a new target for cardiovascular disease therapeutics.血管紧张素转换酶2：心血管疾病治疗的新靶点。
J Cardiovasc Pharmacol. 2007 Aug;50(2):112-9. doi: 10.1097/FJC.0b013e3180986219.
Zotero 插件